Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting 392 enrolled TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Non-randomizedParallel-groupOpen-labelTreatment

Summary

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Timeline

Start: 2024-10-29
Primary completion: 2028-11
Completion: 2028-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BBO-10203	Unknown	—	Oral
Background	Bevacizumab	Monoclonal antibody	—	Other
Background	Fulvestrant	Small molecule	—	Intramuscular
Background	Ribociclib	Small molecule	—	Oral
Background	Trastuzumab	Monoclonal antibody	—	Subcutaneous

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications